Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,110,000 shares, an increase of 378.9% from the December 31st total of 231,800 shares. Based on an average daily volume of 5,910,000 shares, […]
Avenue Therapeutics (NASDAQ:ATXI – Get Free Report) and Geron (NASDAQ:GERN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings. Analyst Recommendations This is a breakdown of current […]
Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 513,700 shares, a growth of 39.0% from the October 15th total of 369,700 shares. Based on an average trading volume of 156,200 shares, […]
Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) Director Lindsay A. Md Rosenwald purchased 348,675 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were bought at an average cost of $0.72 per share, for a total transaction of $251,046.00. Following the acquisition, the director now owns 354,318 shares in […]
Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) Director Lindsay A. Md Rosenwald acquired 348,675 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The stock was purchased at an average price of $0.72 per share, with a total value of $251,046.00. Following the completion of the acquisition, the director […]